Skip to main content
Fig. 5 | Systematic Reviews

Fig. 5

From: A systematic review and meta-analysis assessing antiretroviral therapy for treatment-experienced HIV adult patients using an optimized background therapy approach: is there evidence enough for a standardized third-line strategy?

Fig. 5

Meta-analysis comparing treatment and control groups stratified by study risk of bias. RD, risk difference; CI, confidence interval. *Studies presenting data at week 24. 1Outcome: proportion of patients with < 200 HIV-1 RNA copies/mL. Outcome: proportion of patients with < 50 HIV-1 RNA copies/mL at week 48. Risk of bias categories: high risk of bias (high risk of bias in 2 or more criteria, according to Cochrane Collaboration’s tool for assessing risk of bias, or high risk of bias in 1 criterion and unclear risk of bias in 2 or more criteria), moderate risk of bias (high risk of bias in only 1 criterion and unclear risk of bias in only 1 criterion, or no criteria with high risk of bias and unclear risk of bias in 1 or more criteria), and low risk of bias (all criteria with low risk of bias). Obs. BENCHMRK studies present data in a 96-week follow-up

Back to article page

Systematic Reviews

ISSN: 2046-4053